In ophthalmological clinical trials, sociodemographic disparities still exist.

Published Date: 01 Mar 2023

Ophthalmological Clinical Trials Still Show Sociodemographic Disparities.

Read Full News

Latest News

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Glaucoma Coaches Boost Med Adherence, Study Finds

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

Common Glaucoma Med May Undermine Trabeculectomy Success

Topical brimonidine is linked to a significantly increased risk for trabeculectomy failure in patients with glaucoma due to elevated intraocular pressure.

Endophthalmitis a Risk for Years After Tube Shunt Surgery

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Trabeculectomy Often More Cost-Effective Than Tube Shunts

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Latest News

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Patients who went through the SEE program in Michigan were more likely to stick to their drug regimen and reported less distress related to their condition.

Topical brimonidine is linked to a significantly increased risk for trabeculectomy failure in patients with glaucoma due to elevated intraocular pressure.

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

News All Time

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus Ryan Livingston

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

Recommended News For You

Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.

"We Caught It Early": Advantage or Disadvantage?

Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.

FDA Approves CAR-T Product Use for Myeloma Early.

Interleukin-6 may boost prediction of obesity-related cancers

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma

Recommended Articles For You

Unlocking the Potential of Plinabulin: A New Frontier in Cancer Treatment 

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment 

Everything You Need to Know About HTLV: A Comprehensive Guide  

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Two-part prodrug system activates immune attack only in tumor's unique environment

2.

Oleanolic acid from grapes may increase chemotherapy effectiveness

3.

Obesity-related cancer rising among both younger and older adults worldwide, study finds

4.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

5.

Combination therapy improves outcomes for advanced triple-negative breast cancer

1.

Unlocking the Benefits of Eltrombopag: A Comprehensive Guide

2.

Unveiling the Mystery of Castleman's Disease: A Journey to Better Health

3.

Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics

4.

Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon 

5.

Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

3.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

4.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot